Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia

Abstract

A prospective, open-labelled, multicentre 6-month study was designed to assess three categories that have high impact on Health-Related Quality of Life (HR-QoL). These categories were: satisfaction, preference and drug tolerability in postmenopausal patients with osteoporosis in Croatia, at first treated with weekly oral bisphosphonates, followed by monthly oral ibandronate. Three hundred eighty-five postmenopausal women who were treated with one of the weekly bisphosphonates for at least 6 months were included into the study and after they had signed written informed consent, the therapy was changed to monthly ibandronate. Satisfaction with the treatment was assessed with the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q). Patients completed OPSAT-Q at the baseline visit before the change of therapy (visit 1) and 6 months after the change of therapy (visit 2). Following 6 months ibandronate therapy, the values in all four domains of the OPSAT-Q (convenience, confidence with daily activities, overall satisfaction, side effects) as well as in the Composite Satisfaction Score were higher in visit 2 (p < 0.001). Values in subjects enrolled into the patient assistance programme did not differ significantly from the values in subjects that were not (p = 0.399) except for the domain convenience (p = 0.026). This study demonstrates significantly higher satisfaction in patients who switched from the weekly bisphosphonate therapy regimen to monthly ibandronate in all observed aspects of treatment. Patients expressed preference for monthly bisphosphonate (ibandronate) in comparison with weekly bisphosphonates and found it to be a more convenient method of treatment. At the time of study, however, it was not known that the anti-fracture effect of ibandronate was smaller for hip fractures than with other bisphosphonates.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19(4):399–428

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145–155

    PubMed  Article  Google Scholar 

  3. 3.

    Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD (2007) Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 24(1):37–55

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17(11):1638–1644

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG (2008) Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Clin Ther 30:605–621

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D (2005) Patient preference for once monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Bonviva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895–1903

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 75:303–310

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Kastelan D, Lozo P, Stamenkovic D, Miskic B, Vlak T, Kolak Z, Milas Ahic J, Altabas V, Crncevic Orlic Z, Korsic M (2009) Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study. Clin Rheumatol 28:321–326

    PubMed  Article  Google Scholar 

  9. 9.

    Grazio S, Babic-Naglic D, Kehler T, Curkovic B (2008) Persistence of weekly alendronate: a real-world study in Croatia. Clin Rheumatol 27(5):651–653

    PubMed  Article  Google Scholar 

  10. 10.

    Cook DJ, Guyatt GH, Adachi JD, Clifton J, Griffith LE, Epstein RS, Juniper EF (1993) Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum 36:750–756

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Martin AR, Sornay-Rendu E, Chandler JM, Duboeuf F, Girman CJ, Delmas PD (2002) The impact of osteoporosis on quality-of-life: the Ofely Cohort. Bone 31:32–36

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    de Oliveira FN, Arthuso M, da Silva R, Pedro AO, Neto AM, Costa-Paiva L (2009) Quality of life in women with postmenopausal osteoporosis: correlation between QUALEFFO 41 and SF-36. Maturitas 62:85–90

    Article  Google Scholar 

  13. 13.

    Silverman SL, Minshall ME, Shen W, Harper KD, Xie S, Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study (2001) The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 44:2611–2619

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Strampel W, Emkey R, Civitelli R (2007) Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 30:755–763

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Bonnick SL, Silverman S, Tanner SB, Martens M, Bachmann G, Kohles JD, Civitelli R (2009) Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate. J Womens Health (Larchmt). doi:10.1089/jwh.2008.1064

  16. 16.

    Lambrinoudaki I, Christodoulakos G, Botsis D (2006) Bisphosphonates. Ann N Y Acad Sci 1092:397–402

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, Silverman SL (2009) Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone 44(5):758–765

    PubMed  Article  CAS  Google Scholar 

Download references

Disclosures

TV has received lectures fees from Aventis, Eli Lilly and Roche. DK has received lectures fees from Merck Sharp & Dohme, Roche and Eli Lilly. BM has received lectures fees from Roche. ŽCO has received lectures fees from Merck Sharp & Dohme, Elli Lilly and Roche. MK has received lectures fees from Merck Sharp & Dohme, Aventis, Roche and Servier. PL, JA, MG, ŠM, TN, DC, GT, TD, ZJ, FG, TP, MB, FDž, MSU, MK, MR, MV, ŽK, MP, ER and LJL have no disclosures.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Tonko Vlak.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Vlak, T., Kaštelan, D., Lozo, P. et al. Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia. Clin Rheumatol 30, 1549–1554 (2011). https://doi.org/10.1007/s10067-011-1858-3

Download citation

Keywords

  • Bisphosphonates
  • Ibandronate
  • OPSAT-Q
  • Osteoporosis
  • Quality of life